ISRG

$476.32

Public overview and default valuation.

Log in to track this stock.

Valuation Details
Default assumptions: 10Y forecast, 9% market return, 2.5% terminal growth, 6.88% trendline growth.
Want to create your own valuation? Create a free account.
$148.50

With 20% Margin of Safety (MoS):

$118.80
-75.06% downside
Capital Efficiency
Average Quarterly ROIC
5.35%
Cost of Capital (estimated)7%
Value StatusUnderperforming Capital

The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.

Complete historical ROIC is available with
.
Fundamental Score
46
BearishWeighted across 6 signals
DCF Discount
75.1% premium to price
0
FCF Yield
2.2% trailing FCF yield
4
ROIC vs WACC
ROIC 5.4% vs WACC 7.0% (0.8x)
38
Net Debt / FCF
Net cash position
100
Buybacks
Share count shrinking
80
FCF CAGR (5Y)
12.5% 5Y FCF CAGR
88
Strengths: Net Debt / FCF, Buybacks. Concerns: DCF Discount, FCF Yield.
Narrative Score
78
Improving
Weighted across 6 recent drivers · Last 30 daysVs 6-Month Baseline: High (88th pct)
Trend: StableConfidence: 99%Updated: 5h ago
Sources: 159 (News 146 · Analyst 13)
Drivers
101 news sentiment+2.0
44 regulatory scrutiny+0.7
Analyst upgrades+0.1
Legal risk-0.0
Analyst downgrades-0.0
11 analyst reiterations0.0
Other Metrics
P/E59.2
Profit Margin28.4%
Owner Earnings$4.00b
One Dollar Premise0.00%
Debt/Equity0.13
Current Ratio4.73
PEG14.224
Free Cash Flow (in millions)
20052006200720082009201020112012201320142015201620172018201920202021202220232024
$101$118$230$384$438$624$761$956$985$771$853$1,097$1,335$1,357$2,024$1,826$2,443$2,023$2,878$3,650
How Intrinziq Estimates Fair Value

Intrinziq estimates Intuitive Surgical, Inc.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.

Intuitive Surgical, Inc.Healthcare

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Last updated: Feb 06, 2026
Data sources: Financial Modeling Prep
This valuation is based on assumptions and publicly available data. It is not financial advice or a recommendation to buy or sell any security. Always do your own research before making investment decisions.